Table 3.
Adherence to the 7 domains of secondary prevention.
| Domain | Score | CAD (n = 1113) | PAD (n = 576) | PAD/CAD (n = 314) | Overall (n = 2003) | P-value |
|---|---|---|---|---|---|---|
| Domain 1 | Appropriate use of Antithrombotic Therapy | |||||
| Use of at least one antithrombotic | 1097/1113 (98.6%) | 515/576 (89.4%) | 306/314 (97.5%) | 1918/2003 (95.8%) | < 0,001 | |
| CI 95% | [97.6; 99.1] | [86.5; 91.7] | [94.8; 98.8] | [94.8; 96.6] | ||
| No AF and Infarction < = 365 days | ||||||
| . At least two antiplatelet agents | 161/194 (83%) | 0/0 (NaN%) | 12/20 (60%) | 173/214 (80.8%) | 0.031 | |
| CI 95% | [76.8; 87.8] | – | [36.4; 80.0] | [74.8; 85.8] | ||
| No AF and no infarction or infarction > 36 | ||||||
| . Use of at least one antiplatelet agent | 820/855 (95.9%) | 472/545 (86.6%) | 259/272 (95.2%) | 1551/1672 (92.8%) | < 0,001 | |
| CI 95% | [94.3; 97.1] | [83.4; 89.3] | [91.8; 97.3] | [91.4; 93.9] | ||
| With AF and Infarction < = 365 days | ||||||
| . Use of at least 1 antiplatelet and 1 anticoagulant | 3/6 (50%) | 0/0 (NaN%) | 1/1 (100%) | 4/7 (57.1%) | 1 | |
| CI 95% | [18.8; 81.2] | – | [5.5; 100] | [20.2; 88.2] | ||
| With AF and no infarction or infarction > 365 days | ||||||
| . Use of at least one anticoagulant | 33/58 (56.9%) | 19/31 (61.3%) | 10/21 (47.6%) | 62/110 (56.4%) | 0.662 | |
| CI 95% | [43.3; 69.6] | [42.3; 77.6] | [26.4; 69.7] | [46.6; 65.7] | ||
| Rivaroxaban—vascular dose† | 3/1113 (0.3%) | 19/576 (3.3%) | 9/314 (2.9%) | 31/2003 (1.5%) | ||
| Domain 2 | Cholesterol control†† | |||||
| . High-intensity statin use | 554/1113 (49.8%) | 116/576 (20.1%) | 176/314 (56.1%) | 846/2003 (42.2%) | < 0,001 | |
| CI 95% | [46.8; 52.8] | [17.0; 23.7] | [50.4; 61.6] | [40.1; 44.4] | ||
| . LDL-colesterol < 55 mg/dL | 132/1112 (11.9%) | 13/575 (2.3%) | 27/314 (8.6%) | 172/2001 (8.6%) | < 0,001 | |
| CI 95% | [10.1; 14.0] | [1.3; 3.9] | [5.8; 12.4] | [7.4; 9.9] | ||
| Domain 3 | Blood pressure control | |||||
| . Blood Pressure < 130 × 80 mmHg | 483/1113 (43.4%) | 184/576 (31.9%) | 149/314 (47.5%) | 816/2003 (40.7%) | < 0,001 | |
| CI 95% | [40.5; 46.4] | [28.2; 35.9] | [41.8; 53.1] | [38.6; 42.9] | ||
| . Angiotensin II receptor blockers (ARBs) or ACE inhibitors—Patients with hypertension/Renal disease/heart failure | 861/1007 (85.5%) | 356/465 (76.6%) | 233/299 (77.9%) | 1450/1771 (81.9%) | < 0,001 | |
| CI 95% | [83.1; 87.6] | [72.4; 80.3] | [72.7; 82.4] | [80.0; 83.6] | ||
| . Beta-blocking—Patients with myocardial infarction/heart failure | 735/806 (91.2%) | 32/61 (52.5%) | 181/217 (83.4%) | 948/1084 (87.5%) | < 0,001 | |
| CI 95% | [89.0; 93.0] | [39.4; 65.2] | [77.6; 88.0] | [85.3; 89.3] | ||
| Domain 4 | Glycemic control | |||||
| . HbA1C ≤ 7% | 290/1113 (26.1%) | 59/576 (10.2%) | 67/314 (21.3%) | 416/2003 (20.8%) | < 0,001 | |
| CI 95% | [23.5; 28.8] | [7.9; 13.1] | [17.0; 26.4] | [19.0; 22.6] | ||
| . HbA1C ≤ 7%—Diabetic Patients | 92/452 (20.4%) | 23/289 (8%) | 33/199 (16.6%) | 148/940 (15.7%) | < 0,001 | |
| CI 95% | [16.8; 24.4] | [5.2; 11.9] | [11.8; 22.6] | [13.5; 18.3] | ||
| . Use of metformin and/or GLP-1 receptor agonists and/or SGLT-2 inhibitors—Diabetic Patients | 342/452 (75.7%) | 194/289 (67.1%) | 135/199 (67.8%) | 671/940 (71.4%) | 0.02 | |
| CI 95% | [71.4; 79.5] | [61.3; 72.5] | [60.8; 74.2] | [68.4; 74.2] | ||
| SGLT2 inhibitors/GLP1 agonist—Diabetics | 68/452 (15%) | 16/288 (5.6%) | 33/199 (16.6%) | 117/939 (12.5%) | ||
| Domain 5 | Weight Control | |||||
| . 18.5 kg/m2 < BMI < 25 kg/m2 | 304/1106 (27.5%) | 222/574 (38.7%) | 101/314 (32.2%) | 627/1994 (31.4%) | < 0,001 | |
| CI 95% | [24.9; 30.2] | [34.7; 42.8] | [27.1; 37.7] | [29.4; 33.5] | ||
| Domain 6 | Non-pharmacological intervention | |||||
| . Do not smoke | 976/1113 (87.7%) | 445/576 (77.3%) | 268/314 (85.4%) | 1689/2003 (84.3%) | < 0,001 | |
| CI 95% | [85.6; 89.5] | [73.6; 80.6] | [80.8; 89.0] | [82.6; 85.9] | ||
| . > 150 min per week of physical activity | 196/1113 (17.6%) | 33/576 (5.7%) | 22/314 (7%) | 251/2003 (12.5%) | < 0,001 | |
| CI 95% | [15.4; 20.0] | [4.0; 8.0] | [4.5; 10.6] | [11.1; 14.1] | ||
| Total | Total score; n/N(%) | 5/1105 (0.5%) | 0/573 (0%) | 0/314 (0%) | 5/1992 (0.3%) | 0.233 |
| CI 95% | [0.2; 1.1] | [0.0; 0.8] | [0.0; 1.5] | [0.1; 0.6] | ||
†10 patients took rivaroxaban 2.5 mg 1x/day and 1 patient takes rivaroxaban 5.0 mg 1x/ day. ††Use of fibrate 2.1%, ezetimibe 8.8% and anti-PCSK9 only in 2 patients. CAD means coronary artery disease; PAD means peripheral artery disease; CI means standard confidence interval; AF means atrial fibrillation.